In 2008, Evotec acquired US-based Renovis in a $152 million stock deal, allowing it to list on the Nasdaq stock exchange. One year later, the company announced it was voluntarily de-listing its American Depositary Receipt to cut costs and concentrate its share trading on the German TecDAX platform.
In 2010, the company acquired DeveloGen AG, a spin-out from the Max Planck Institute for Biophysical Chemistry that was developing novel therapies for metabolic disorders, such as diabetes.
In 2011, Evotec acquired Kinaxo Biotechnologies GmbH, a Munich-based, privately owned biotech company. Kinaxo specialized in chemical proteomics and its application in small molecule drug discovery. That same year, Evotec took control of Compound Focus the compound management arm of the Galapagos group subsidiary Biofocus.
In January 2013, Evotec acquired CCS Cell Culture Service GmbH, a Hamburg-based company that supplied custom cells and cell-based reagents for drug discovery applications.
Read the full text
In May 2014, Evotec acquired Euprotec for $3.15 million, a contract research organization (CRO) with expertise in infectious diseases and respiratory biology.
In December 2016, Evotec completed its acquisition of Cyprotex, a preclinical contract research organization.
In July 2017, Evotec acquired the integrated drug development services provider Aptuit for €256 million.
In recent years, Evotec has made two significant deals with French pharmaceutical company Sanofi. In 2015, Evotec took over Sanofi's small-molecule drug development site in Toulouse, France, bringing approximately 200 Sanofi chemists into its team. In 2018, Evotec acquired Sanofi's infectious disease unit, absorbing an additional 100 Sanofi employees and a majority of its anti-infectives research portfolio, including more than 10 R&D assets. Per the agreement, Evotec will continue to run infectious disease R&D operations in Lyon, France. Evotec's initial focus will be on antimicrobial resistance ("AMR") and superbug infections, tuberculosis, and malaria, as well as the creation of novel antiviral therapies with new mechanisms of action.
In April 2019, Evotec AG announced it had completed its conversion into a company under European law (Societas Europaea, "SE"). It officially adopted the legal name Evotec SE, with its registration in the commercial register of the District Court of Hamburg.
In May 2020, the company announced its acquisition of Just Biologics, a U.S.-based biologics company previously backed by the Gates Foundation.
In June 2020, Evotec and two investment partners – Samsara BioCapital and KCK Ltd. – announced the launch of Autobahn Labs, a virtual incubator for early-stage research programs, headquartered in Palo Alto, California.
In May 2022, Evotec announced the company are set to acquire Italy-based cell technology firm Rigenerand. The deal worth $24.5 million will include Evotec EVOcells cell therapy platform to Rigenerand's cGMP.
